VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | A potential novel hemophilia treatment: an in vitro study of eptacog beta and emicizumab

Steven Pipe, MD, University of Michigan, Ann Arbor, MO, discusses a study aiming to evaluate the in vitro effects of eptacog beta and emicizumab on thrombin generation in congenital hemophilia A (HA) plasma, with and without inhibitors. Emicizumab, a routine prophylaxis treatment in many HA patients, is a novel, bispecific antibody with pro-coagulation properties, the use of which has previously been linked to serious arterial or venous thrombotic events. In combination with eptacog alpha, however, there seems to be no such risk. Similar results were found in this in vitro study when using the combined eptacog beta and emicizumab treatment, indicating that this line of therapy has potential in HA, allowing patients to be treated without a risk of potentially dangerous high thrombogeneration levels.This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.


Consulting: Apcintex, Bayer, Biomarin, Catalyst Biosciences, CSL Behring, HEMA Biologics, Freeline, Novo Nordisk, Pfizer, Roche/Genentech, Sangamo Therapeutics, Sanofi, Takeda, Spark Therapeutics, uniQure

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter